（文章来源：证券日报） 证券日报网讯 1月15日，贝达药业在互动平台回答投资者提问时表示，杭州知兴制药有限公司专注于高 端吸入制剂研发与生产，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实 验室到产业化落地的能力。公司投资知兴制药，布局高端吸入制剂领域，符合公司长期发展战略，双方 围绕创新研发、技术平台等领域开展深度合作，有助于拓展公司新药创制技术平台，进一步拓宽疾病治 疗领域的战略布局。 ...

Core Viewpoint - Beida Pharmaceutical has completed a share transfer agreement with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, aiming to enhance its position in the biopharmaceutical sector and strengthen its ecosystem in high-barrier technology areas [1] Group 1 - Beida Pharmaceutical's investment in Hangzhou Zhixing Pharmaceutical is part of its strategy to leverage its advantages in the biopharmaceutical field [1] - The company aims to continuously improve its ecosystem layout around high-barrier technology [1] - The acquisition involves a total registered capital of 200 million yuan for Zhixing Pharmaceutical, indicating a significant commitment to the partnership [1] Group 2 - Hangzhou Zhixing Pharmaceutical specializes in the development of high-end inhalation formulations [1] - The core technical team of Zhixing Pharmaceutical has a strong industry background, which is crucial for its operations [1] - Zhixing Pharmaceutical has established a comprehensive research and production system, demonstrating its capability to transition products from laboratory to industrialization [1]

Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Company Investment - The company invested 50 million yuan to acquire the 200 million yuan registered capital of Zhixing Pharmaceutical [1] - This investment aligns with the company's long-term development strategy in the high-end inhalation formulation sector [1] Group 2: Industry Overview - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] - These formulations are recommended as the preferred treatment method for asthma and chronic obstructive pulmonary disease (COPD) in domestic and international guidelines [1] - Inhalation formulations are expanding into other fields, including vaccines and central nervous system applications, and are being explored for lung cancer treatment due to their targeted delivery and flexibility [1]

Core Viewpoint - Beida Pharmaceutical has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, which will enhance its new drug development technology platform and expand its strategic layout in disease treatment [1] Group 1 - Beida Pharmaceutical invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [1] - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations and has established a comprehensive R&D and production system [1] - The investment does not constitute a related party transaction or a major asset restructuring, and does not require approval from relevant authorities [1] Group 2 - This investment will help Beida Pharmaceutical to broaden its strategic layout in the field of disease treatment [1]

Core Viewpoint - Zhejiang's industrial economy is crucial for economic stability and growth, with significant contributions from key industrial cities and counties, as highlighted by the recent evaluation of "Industrial Cities and Counties Taking the Lead" [1][19]. Group 1: Industrial Cities and Counties Taking the Lead - Zhejiang has 45 industrial counties, representing half of the province's total counties, with 5 major cities and 20 counties recognized for their contributions [5][23]. - From January to November last year, these cities and counties contributed 58.5% and 52.6% to the province's growth, respectively, showcasing their leadership role [6][23]. - Notable cities like Shaoxing and Wenzhou achieved industrial value-added growth rates of 9.8% and 10.3%, significantly above the provincial average of 7.0% [6][23]. - Wenzhou has consistently outperformed, with 33 months of growth exceeding national and provincial rates, and signed major projects exceeding 100 billion yuan each quarter [6][23]. Group 2: Contributions from Industrial Counties - Among the 20 recognized counties, 8 reported growth rates above 10%, with Yiwu leading at 12.2%, demonstrating resilience in a challenging trade environment [8][25]. - Yiwu's focus on high-quality manufacturing and emerging industries has resulted in over 50% of its industrial output coming from new sectors [8][25]. - Newcomers like Kecheng and Wucheng also showed impressive growth rates of 12.5% and 12.4%, indicating a strong upward trend in industrial development [10][28]. Group 3: Contributions from Non-Industrial Counties - The evaluation identified 10 non-industrial counties making significant contributions, with Longgang City leading in manufacturing investment growth [29][30]. - Longgang's first major manufacturing project, a high-performance automotive wheel hub production base, is expected to generate an annual output value of 1 billion yuan [30][32]. - East Yang and Taizhou's Road Bridge District also made notable advancements in manufacturing investment, reflecting a broader trend of industrial growth across various regions [12][33]. Group 4: Innovation Development - The "Innovation Development" category recognized 10 counties excelling in innovation, with Hangzhou's Binjiang District and New Changxiang leading the way [16][34]. - Binjiang District achieved significant growth in high-tech and strategic emerging industries, maintaining double-digit growth rates [34]. - Emerging areas like Qujiang District and Daishan County are also making strides in innovation, focusing on enhancing product value and core competitiveness [36][36].